<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        85-68-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SPIRIVA 18MCG HARD CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIOTROPIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation powder, hard capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Inhaler
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        142.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BOEHRINGER INGELHEIM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03BB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIRIVA 18&nbsp;microgram makes it easier for patients with chronic obstructive pulmonary disease (COPD) to breathe. Chronic obstructive pulmonary disease (COPD) is a permanent lung disease accompanied by shortness of breath and cough. The term COPD is also used as a name to cover the symptoms of chronic obstructive bronchitis and emphysema. COPD is a chronic disease, so you should use SPIRIVA 18&nbsp;microgram every day and not just when you have breathing problems or other symptoms of COPD.</p><p>&nbsp;</p><p>SPIRIVA is a long-acting bronchodilator that expands the airways and thereby makes it easier for the lungs to breathe in and out. Regular use of SPIRIVA can alleviate the shortness of breath that occurs in this disease, thereby boosting physical activity and helping you to reduce the effects of the disease on your everyday life.</p><p>&nbsp;</p><p>Daily use of SPIRIVA may furthermore prevent the onset of acute (sudden) temporary episodes of worsening disease, which may last for up to several days.</p><p>The effect of this medicine lasts for 24&nbsp;hours, so SPIRIVA only needs to be used once a day.</p><p>For details on correct dosing of SPIRIVA, see section&nbsp;3. &ldquo;How to use SPIRIVA 18&nbsp;microgram&rdquo;, and section &ldquo;Instructions for use of the HandiHaler device&rdquo;, provided at the end of this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use SPIRIVA 18&nbsp;microgram</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to the active substance tiotropium or to the excipient lactose monohydrate listed in section&nbsp;6. (may contain small amounts of milk proteins);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to atropine or derivatives of this substance, e.&nbsp;g. ipratropium or oxitropium.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before using SPIRIVA.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you suffer from narrow-angle glaucoma or prostate problems or have difficulties in passing urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you have problems with your kidneys.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPIRIVA 18&nbsp;microgram is indicated for the long-term treatment of your chronic obstructive pulmonary disease; it should not be used to treat sudden attacks of breathlessness or wheezing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediate-type allergic reactions, such as rash, swelling, itching, wheezing or breathlessness, may occur after the use of SPIRIVA. If this happens, please contact your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhaled medicines such as SPIRIVA may cause chest tightness, coughing, wheezing or breathlessness immediately after inhalation. If this happens, please contact your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Care must be taken that the inhalation powder does not get into the eyes, as this may cause narrow-angle glaucoma (increased inner eye pressure) to occur or make it worse. Eye pain or discomfort, blurred vision, eye halos (coloured rings around light sources) or false colour perception together with red eyes may be signs of an acute glaucoma attack. Eye symptoms may be accompanied by headache, nausea or vomiting. If these signs or symptoms occur, you should stop treatment with tiotropium bromide and seek medical advice immediately; if possible, from an eye specialist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth, which has been observed during treatment with medicines of this group of active substances (anticholinergics), might lead to tooth delay (caries) if it persists over prolonged periods. Thorough dental hygiene must therefore be ensured.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had a heart attack in the last 6&nbsp;months, or unstable or life‑threatening heart rhythm disorders or severe heart failure (cardiac insufficiency) in the past 12&nbsp;months, please tell your doctor. This is important when deciding whether SPIRIVA is suitable for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use SPIRIVA more frequently than once a day.</p><p>&nbsp;</p><p>Children and adolescents</p><p>&nbsp;</p><p>SPIRIVA 18&nbsp;microgram is not recommended for children and adolescents under 18&nbsp;years of age.</p><p>&nbsp;</p><p>Other medicines and SPIRIVA 18&nbsp;microgram</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines. This includes medicines obtained without a prescription.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are using or have recently used similar medicines for your lung disease, such as ipratropium or oxitropium.</p><p>&nbsp;</p><p>No specific side effects have been observed with use of SPIRIVA 18&nbsp;microgram together with other medicines for the treatment of COPD, such as inhalants for acute symptoms (e.&nbsp;g. salbutamol), methylxanthines (e.&nbsp;g. theophylline) and/or oral and inhaled steroids (e.&nbsp;g. prednisolone).</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. You should not use this medicine unless it is specifically recommended by your doctor.</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>This medicine may impair the ability to drive or use machines, due to the onset of dizziness, blurred vision or headache.</p><p>&nbsp;</p><p>SPIRIVA 18&nbsp;microgram contains lactose monohydrate</p><p>&nbsp;</p><p>When SPIRIVA 18&nbsp;microgram is used as directed at the recommended dose, i.&nbsp;e. 1&nbsp;capsule daily, up to 5.5&nbsp;mg lactose monohydrate may be released. If you have been told by your doctor that you have an intolerance to some sugars or an allergy to milk proteins (which may be present in small amounts in lactose monohydrate), contact your doctor before using this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Recommended dose: Inhale the contents of 1&nbsp;capsule (18&nbsp;micrograms of tiotropium) once a day. Do not inhale more than 1&nbsp;capsule per day.</p><p>&nbsp;</p><p>The capsule contents should be inhaled at the same time each day. This is important because the effect of SPIRIVA lasts for 24&nbsp;hours.</p><p>&nbsp;</p><p>The capsules are intended for inhalation only, not for oral use.</p><p>The capsules must not be swallowed.</p><p>&nbsp;</p><p>The HandiHaler inhaler, into which the SPIRIVA capsule is inserted, pierces the capsule at the push of a button, thereby allowing inhalation of the powder.</p><p>&nbsp;</p><p>Make sure you have a HandiHaler device and can use it properly. Read the section &ldquo;Instructions for use of the HandiHaler device&rdquo; at the end of this leaflet.</p><p>&nbsp;</p><p>Be careful not to breathe into the HandiHaler.</p><p>&nbsp;</p><p>If you have problems using the HandiHaler, ask your doctor, nurse or pharmacist to show you how to use it properly.</p><p>&nbsp;</p><p>You should clean the HandiHaler once a month, as described in the &rdquo;Instructions for use of the HandiHaler device&rdquo; at the end of this leaflet.</p><p>&nbsp;</p><p>When using SPIRIVA 18&nbsp;microgram, make sure that the inhalation powder does not get into your eyes. If the inhalation powder gets into your eyes and symptoms occur, such as blurred vision, eye pain and/or red eyes, rinse your eyes immediately with lukewarm water. Seek medical advice immediately.</p><p>&nbsp;</p><p>If you feel that your breathing is getting worse, tell your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>&nbsp;</p><p>SPIRIVA 18&nbsp;microgram is not recommended for children and adolescents under 18&nbsp;years of age.</p><p>&nbsp;</p><p>If you use more SPIRIVA 18&nbsp;microgram than you should</p><p>&nbsp;</p><p>If you inhale more than one capsule of SPIRIVA 18&nbsp;microgram per day, you should talk to your doctor immediately. You might be at greater risk of experiencing side effects such as dry mouth, constipation, discomfort when passing urine, palpitations or blurred vision.</p><p>&nbsp;</p><p>If you forget to use SPIRIVA 18&nbsp;microgram</p><p>&nbsp;</p><p>If you forget to inhale a dose at your scheduled time, make up for it as soon as possible. However, you must not inhale a double dose (2&nbsp;capsules) all at once or on the same day. Then continue with your next dose as usual.</p><p>&nbsp;</p><p>If you stop using SPIRIVA</p><p>&nbsp;</p><p>Before you stop using SPIRIVA, talk to your doctor or pharmacist.</p><p>If you stop using SPIRIVA, the symptoms and discomfort of COPD may increase.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The side effects described below have occurred in patients using SPIRIVA and are listed as common, uncommon, rare or not known, according to their frequency.</p><p>&nbsp;</p><p>Common (may affect up to 1&nbsp;in 10&nbsp;patients treated):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth: This is usually mild</p><p>&nbsp;</p><p>Uncommon (may affect up to 1&nbsp;in 100&nbsp;patients treated):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heartbeat (atrial fibrillation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the throat (pharyngitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hoarseness (dysphonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn (gastro-oesophageal reflux disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections of the oral cavity and throat (oropharyngeal candidiasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties passing urine (urinary retention)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful urination (dysuria)</p><p>&nbsp;</p><p>Rare (may affect up to 1&nbsp;in 1,000&nbsp;patients treated):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seeing halos around lights or coloured images in association with red eyes (glaucoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of the measured eye pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heartbeat (supraventricular tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Faster heartbeat (tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling your heartbeat (palpitations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tightness of the chest, associated with coughing, wheezing or breathlessness immediately after inhalation (bronchospasm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nosebleed (epistaxis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the larynx (laryngitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the sinuses (sinusitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blockage of intestines or absence of bowel movements (intestinal obstruction including ileus paralytic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the gums (gingivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tongue (glossitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties swallowing (dysphagia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mouth (stomatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity, including immediate reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction which causes swelling of the face or throat (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nettle rash (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching (pruritus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the urinary tract</p><p>&nbsp;</p><p>Frequency not known (frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depletion of body water (dehydration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dental caries</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction (anaphylactic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections or ulcerations of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dryness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of joints</p><p>&nbsp;</p><p>Serious side effects include allergic reactions with swelling of the face or throat (angioedema) or other hypersensitivity reactions (such as sudden drop in blood pressure or dizziness). These can occur either individually or as part of a severe allergic reaction (anaphylactic reaction) after use of SPIRIVA 18&nbsp;microgram. As with all inhaled medicines, chest tightness, coughing, wheezing or shortness of breath (bronchospasm) may occur unexpectedly in some patients immediately after inhalation. In such cases, tell your doctor immediately.</p><p>&nbsp;</p><p>This medicine contains lactose monohydrate. Lactose monohydrate may contain small amounts of milk proteins and may therefore cause allergic reactions.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after &ldquo;Use-by date&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>After removing the first capsule from a blister, the opened blister should be emptied by using one capsule daily over the next 9&nbsp;days.</p><p>Discard the HandiHaler device 12&nbsp;months after first use.</p><p>&nbsp;</p><p>Do not store above 25&deg;C.</p><p>Do not freeze.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tiotropium. Each capsule contains 18&nbsp;micrograms of the active substance tiotropium (as tiotropium bromide&nbsp;1&nbsp;H<sub>2</sub>O).</p><p>At each inhalation, 10&nbsp;micrograms of tiotropium are delivered from the mouthpiece of the HandiHaler.</p><p>&nbsp;</p><p>The other ingredient is lactose monohydrate (may contain small amounts of milk proteins).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                SPIRIVA 18 microgram is an inhalation powder in a light-green, hard capsule printed with the product code “TI 01” and the company logo.

SPIRIVA 18 microgram is available in the following pack sizes:
Pack with 30 capsules
Pack with 60 capsules
Pack with 90 capsules
Combination pack with 30 capsules and 1 HandiHaler

The HandiHaler (inhaler) is also available separately.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>&nbsp;</p><p>Marketing Authorisation Holder</p><p>Boehringer Ingelheim International GmbH</p><p>Binger Str. 173</p><p>55216&nbsp;Ingelheim am Rhein</p><p>Germany</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Boehringer Ingelheim Pharma GmbH &amp; Co. KG</p><p>Binger Str. 173</p><p>55216&nbsp;Ingelheim am Rhein</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2023 (EU SPC) 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يجعل سبيريفا 18 ميكروجرامًا التنفس أسهل بالنسبة لمرضى الانسداد الرئوي المُزمِن. يُعد مرض الانسداد الرئوي المزمن بمثابة مرض رئوي دائم مصحوب بضيق التَّنفس والسعال. كما يُستخدم المصطلح &quot;مرض الانسداد الرئوي المزمن/COPD&quot; كاسم يندرج تحته أعراض التهاب الشعب الهوائية الانسدادي المزمن والانتفاخ الرئوي. مرض الانسداد الرئوي المُزمِن هو مرض مزمن ولذا يجب عليك استنشاق سبيريفا 18ميكروجرامًا كل يوم وليس فقط عند مواجهة مشاكل في التنفس أو غيرها من أعراض مرض الانسداد الرئوي المُزمِن.</p><p>&nbsp;</p><p dir="RTL">يُعد سبيريفا موسعًا للشعب طويل المفعول؛ حيث يعمل على توسيع الممرات الهوائية وبالتالي يسهل عملية الشهيق والزفير من الرئتين وإليهما. كما أنَّ الاستخدام المنتظم لسبيريفا يمكن أن يخفف من ضيق التنفس الذي يحدث في هذا المرض، وبالتالي سيُؤدي إلى تعزيز النشاط البدني وسيساعد على الحد من تأثيرات المرض على حياتك اليومية.</p><p>&nbsp;</p><p dir="RTL">علاوة على ذلك، قد يمنع الاستخدام اليومي لسبيريفا ظهور نوبات مؤقتة حادة (مفاجئة) من تفاقم المرض، والتي قد تستمر لمدة تصل إلى عدة أيام.</p><p dir="RTL">يستمر تأثير هذا الدواء لمدة 24 ساعة، لذا ستكون بحاجة إلى تناول&nbsp; سبيريفا مرة واحدة فقط في اليوم.</p><p dir="RTL">لمعرفة تفاصيل حول الجرعات الصحيحة من سبيريفا، يرجى مراجعة قسم: 3. &quot;كيفية استخدام سبيريفا 18 ميكروجرامًا&quot;، والقسم &quot;تعليمات استخدام جهاز الاستنشاق هاندي هيلر&quot; بنهاية هذه النَّشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم سبيريفا 18&nbsp;ميكروجرامًا في الحالات التَّالية:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية (حساسية مفرطة) تجاه المادة الفعَّالة تيوتروبيوم أو تجاه السواغ (المادة غير الفعالة) لاكتوز أحادي الهيدرات المذكور في قسم: 6. (ربما يحتوي على كميات قليلة من بروتينات الحليب)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية (حساسية مفرطة) تجاه الأتروبين أو مشتقات هذه المادة، على سبيل المثال: مثل إبراتروبيوم أو أوكسيتروبيوم.</p><p>&nbsp;</p><p>تحذيرات واحتياطات</p><p>&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام سبيريفا.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك إذا كنت تعاني من زَرَق ضَيِّق الزَّاوِيَة / الجلوكوما أو مشاكل في البروستاتا أو صعوبة في التبول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث مع طبيبك إذا كان لديك مشاكل في الكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدَم سبيريفا 18 ميكروجرامًا كعلاج طويل الأمد لمرض الانسداد الرئوي المزمن، لا يجب استخدامه لعلاج النوبات المفاجئة من عُسْر التَّنَفُّس أو أزيز الصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث تفاعلات حساسية من النوع الفوري مثل الطفح الجلدي، التورم، الحكة، أزيز الصدر أو عُسْرُ التَّنَفُّس بعد استخدام سبيريفا. إذا حدث ذلك، فاتصل بطبيبك فورًا من فضلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُسبب الأدوية التي يتم استخدامها عن طريق الاستنشاق مثل سبيريفا ضيق في الصدر أو السعال أو الأزيز أو عُسْرُ التَّنَفُّس بعد استنشاقها مباشرةً. إذا حدث ذلك، فاتصل بطبيبك فورًا من فضلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب توخي الحذر للتأكُّد من عدم وصول مسحوق الاستنشاق إلى عينيك، لأن ذلك قد يتسبب في حدوث زرق ضيِّق الزاوية/الجلوكوما (ارتفاع الضغط داخل العين) أو يزيد الأمر سوءًا. حدوث ألم أو إحساس غير مريح بالعين، أو عدم وضوح الرؤية، أو رؤية الهالات (رؤية حلقات ملونة حول مصادر الضوء) أو إدراك خاطئ للألوان مع احمرار بالعينين قد تكون علامات لنوبة حادة من زَرَق ضيق الزاوية/ الجلوكوما. قد يصاحب أعراض العين، الصداع أو الغثيان أو القيء. إذا حدثت أيٌّ من هذه العلامات أو الأعراض، فيجب عليك وقف العلاج ببروميد تيوتروبيوم وطلب المساعدة الطبية فورًا؛ من أخصائي عيون إن أمكن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي جفافُ الفَم، الذي لوحظ أثناء العلاج بأدوية من هذه المجموعة من المواد الفعالة (مضادات الفعل الكوليني)، إلى تسوس الأسنان إذا استمر لفترات طويلة. لذلك يجب الحفاظ على نظافة الأسنان تمامًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بنوبة قلبية في الأشهر الستة الماضية، أو كنت تعاني من اضطرابات النَّظْم القلبي غير المستقرة أو المهددة للحياة أو فشل القلب الشديد (قصور القلب) خلال الـ 12 شهرًا الماضية، فيرجى إخبار طبيبك. هذا الأمر مهم عند اتخاذ قرار بشأن ما إذا كان سبيريفا مناسبًا لك أم لا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم سبيريفا بمعدل تكرار أكثر من مرة واحدة يوميًّا.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p>&nbsp;</p><p dir="RTL">لا يُوصى بسبيريفا 18 ميكروجرامًا في الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p>&nbsp;</p><p>استخدام&nbsp; سبيريفا 18 ميكروجرامًا مع أدوية أخرى</p><p>&nbsp;</p><p dir="RTL">أخبر الطبيب أو الصيدلي الخاص بك إذا كنت تتناول/تستخدم، أو تناولت/استخدمت مؤخرًا أو قد تتناول/تستخدم أيَّة أدوية أخرى. يشمل ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p>&nbsp;</p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي إذا كنت تستخدم أو استخدمت مؤخرًا أدوية مماثلة لعلاج مرض الرئة الذي تعاني منه، مثل إبراتروبيوم أو أوكسيتروبيوم.</p><p>&nbsp;</p><p dir="RTL">لم تلاحظ أي آثار جانبية محددة عند استخدام سبيريفا 18 ميكروجرامًا مع أدوية أخرى لعلاج مرض الانسداد الرئوي المُزمِن، مثل أدوية الاستنشاق للأعراض الحادة (على سبيل المثال سالبوتامول)، والميثيلزانثينات (على سبيل المثال: ثيوفيلين) و/أو الستيرويدات عن طريق الفم أو الاستنشاق (على سبيل المثال بريدنيزولون).</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُل هذا الدَّواء. ينبغي عليكِ ألا تستخدمي هذا الدواء ما لم يوصِ به طبيبكِ على وجه التحديد.</p><p>&nbsp;</p><p>القيادة واستخدام الآلات</p><p>&nbsp;</p><p dir="RTL">قد يُضعف هذا الدَّواء قدرتك على القيادة أو استخدام الآلات، بسبب حدوث الدوخة أو عدم وضوح الرؤية أو الصداع.</p><p>&nbsp;</p><p>يحتوي سبيريفا 18 ميكروجرامًا على لاكتوز أحادي الهيدرات.</p><p>&nbsp;</p><p dir="RTL">عندما يتم استخدام سبيريفا 18 ميكروجرامًا حسب التوجيهات بالجرعة الموصى بها، أي: كبسولة واحدة يوميًّا، قد يتم إفراز ما يصل إلى 5.5 مجم من اللاكتوز أحادي الهيدرات. إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات أو أن لديك حساسية تجاه بروتينات الحليب (والتي قد تتواجد بكميات صغيرة في اللاكتوز أحادي الهيدرات)، فاتصل به قبل استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. يُرجى مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p>&nbsp;</p><p dir="RTL">الجرعةلموصى بها: استنشق محتويات كبسولة واحدة (18 ميكروجرامًا من تيوتروبيوم) مرة واحدة في اليوم. لا تستنشق أكثر من كبسولة واحدة في اليوم.</p><p>&nbsp;</p><p dir="RTL">يجب استنشاق محتويات الكبسولة في الوقت نفسه من كل يوم. هذا الأمر مهم لأن تأثير سبيريفا يستمر لمدة 24 ساعة.</p><p>&nbsp;</p><p dir="RTL">الكبسولات معدة للاستنشاق فقط وليس للتناوُل عن طريق الفم.</p><p dir="RTL">يجب عدم ابتلاع الكبسولات.</p><p>&nbsp;</p><p dir="RTL">جهاز الاستنشاق هاندي هيلر، الذي يتم إدخال كبسولة سبيريفا فيه، يخرق الكبسولة بضغطة زر، مما يسمح باستنشاق المسحوق.</p><p>&nbsp;</p><p dir="RTL">احرص على أن يكون لديك جهاز هاندي هيلر وتأكد من أنه يمكنك استخدامه بالشكل السليم. يُرجى قراءة قسم &quot;تعليمات استخدام جهاز الاستنشاق هاندي هيلر&quot; في نهاية هذه النَّشرة.</p><p>&nbsp;</p><p dir="RTL">احرص على عدم التنفس في جهاز الاستنشاق هاندي هيلر.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك مشاكل متعلقة باستخدام جهاز الاستنشاق هاندي هيلر، فاطلب من طبيبك أو الممرضة أو الصيدلي أن يريك طريقة استخدامه بشكل سليم.</p><p>&nbsp;</p><p dir="RTL">يجب عليك تنظيف جهاز الاستنشاق هاندي هيلر مرة واحدة في الشهر، على النحو المبين في قسم &quot;تعليمات استخدام جهاز الاستنشاق هاندي هيلر&quot; في نهاية هذه النَّشرة.</p><p>&nbsp;</p><p dir="RTL">عند استخدام سبيريفا 18 ميكروجرامًا، تأكد من عدم دخول مسحوق الاستنشاق في عينيك. إذا دخل مسحوق الاستنشاق في عينيك وحدثت أعراض، مثل عدم وضوح الرؤية، ألم العين و/أو احمرار العينين، فاشطف عينيك على الفور بماء فاتر. اطلب المشورة الطبية على الفور.</p><p>&nbsp;</p><p dir="RTL">إذا شعرت بأن تَّنَفُّسك يسوء، فأخبر طبيبك في أسرع وقت ممكن.</p><p>&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p>&nbsp;</p><p dir="RTL">لا يُوصى بسبيريفا 18 ميكروجرامًا في الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p>&nbsp;</p><p>في حالة استخدام كمية أكثر مما يجب من سبيريفا 18 ميكروجرامًا</p><p>&nbsp;</p><p dir="RTL">إذا استنشقت أكثر من كبسولة واحدة من سبيريفا 18 ميكروجرامًا في اليوم، فيجب إبلاغ طبيبك فورًا. قد تكون معرضًا بصورة أكبرلخطر حدوث آثار جانبية ، مثل: جفاف الفَم، الإمساك، الشعور بعدم الراحة عند التبول، الخَفَقان أو عدم وضوح الرؤية.</p><p>&nbsp;</p><p>إذا أغفلت استخدام سبيريفا 18 ميكروجرامًا</p><p>&nbsp;</p><p dir="RTL">إذا أغفلت استنشاق إحدى الجرعات في وقتها المقرر، فقم بتعويضها في أسرع وقت ممكن. ولكن يجب ألا تستنشق جرعة مضاعفة (كبسولتين) معًا أو في اليوم نفسه. بعد ذلك يمكنك الاستمرار في تناول جرعتك التَّالية على النحو المعتاد.</p><p>&nbsp;</p><p>إذا توقفت عن استخدام سبيريفا</p><p>&nbsp;</p><p dir="RTL">قبل أن تتوقف عن استخدام سبيريفا، يجب عليك التَّحدث إلى طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">إذا توقفت عن استخدام سبيريفا، فقد تزيد أعراض مرض الانسداد الرئوي المُزمِن والشعور بعدم الراحة الناجم عنه.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p>&nbsp;</p><p dir="RTL">الآثار الجانبية الموضحة أدناه حدثت لدى مرضى يستخدمون سبيريفا وتم سردها وفقًا لمعدل تكرارها إما شائعة أو غير شائعة أو نادرة أو غير معروف معدَّل تكرارها.</p><p>&nbsp;</p><p dir="RTL">شائعة (قد تُؤثر على ما يصل إلى مريض واحد من كل 10&nbsp;مرضى يتم علاجهم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم: عادة ما يكون خفيفًا</p><p>&nbsp;</p><p dir="RTL">غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض يتم علاجهم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب غير منتظمة (الرجفان الأذيني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق (التهاب البلعوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بحة في الصوت (اضطرابات صوتية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحموضة (مرض الجَزْر/الارتجاع المَعِدِيّ المَريئِ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية بالتجويف الفموي والحَلْق (داء المبيضات الفَمَوِي البُلْعومِيّ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التبول (احتباس البول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم عند التبول (عسر التبول)</p><p>&nbsp;</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 1000&nbsp;مريض يتم علاجهم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (أرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية هالات حول الأضواء أو الصور الملونة مع احمرار العينين (الجلوكوما (الزَرَق))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الضغط داخل العين عند قياسه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القَلْب (تسرُّع ضربات القَلْب فوق البطيني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع ضربات قلب (تسرُّع القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضربات القلب (خفقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر، مصحوب بسعال أو أَزيز بالصدر أو عسر التنفس بعد الاستنشاق مباشرةً (تشنج قصبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاف (نزيف الأنف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحنجرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهابُ الجُيوب الأنفية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء أو غياب&nbsp; حركة الأمعاء (انسداد الأمعاء، بما في ذلك العلوص الشللي(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب اللثة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في البلع (عسر البلع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (غثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فَرْطُ الحساسية، بما في ذلك التفاعلات الفورية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة والتي تسبب تورم الوجه أو الحلق (وذمة وعائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح القراص (أرتكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية</p><p>&nbsp;</p><p dir="RTL">معدل التكرار غير معروف (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نفاد المياه بالجسم (جفاف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسوس الأسنان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد (تفاعل تَأَقِيّ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى أو تقرحات بالجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم المفاصل</p><p>&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية الخطيرة تفاعلات حساسية مصحوبة بتورم الوجه أو الحلق (وذمة وعائية) أو تفاعلات فرط حساسية أخرى (مثل الانخفاض المفاجئ في ضغط الدَّم أو الدوخة). وهي قد تحدث إما بشكل فردي أو كجزء من أحد تفاعلات الحساسية الشديدة (تفاعل تَأَقِيّ) بعد استخدام سبيريفا 18 ميكروجرامًا. كما هو الحال مع جميع الأدوية المستنشقة، قد يحدث ضيق في الصدر، سعال، أزيز في الصدر أو ضيق النفس (التشنج القصبي) بشكل غير متوقع لدى بعض المرضى بعد الاستنشاق مباشرة. فأخبر طبيبك فورًا في مثل هذه الحالات.</p><p>&nbsp;</p><p dir="RTL">يحتوي هذا الدَّواء على لاكتوز أحادي الهيدرات. ربما يحتوي اللاكتوز أحادي الهيدرات على كميات قليلة من بروتينات الحليب، وبالتالي فربما يسبب تفاعلات حساسية.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. يشمل ذلك أيَّة آثار جانبية مُحتمَلة غير مُدرَجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على الشريط والعبوة الكرتونية بعد كلمة &quot;Use-by date&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">بعد إخراج الكبسولة الأولى من الشريط، يجب استخدام الشريط المفتوح إلى أن يفرغ عن طريق استخدام كبسولة واحدة يوميًّا منه على مدار الأيام التسعة التالية.</p><p dir="RTL">تخلص من جهاز الاستنشاق هاندي هيلر بعد 12 شهرًا من استخدامه لأول مرة.</p><p>&nbsp;</p><p dir="RTL">لا تقم بالتَّخزين في درجة حرارة تتعدى 25 درجة مئوية.</p><p dir="RTL">لا تعرضه للتجميد.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق إلقائها في مياه الصرف. استشِر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. تلك الإجراءات ستُساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي تيوتروبيوم. تحتوي كل كبسولة على 18 ميكروجرامًا من المادة الفعالة تيوتروبيوم (على هيئة بروميد تيوتروبيوم 1 المائي).</p><p dir="RTL">في كل مرة استنشاق، يتم سحب 10 ميكروجرامات من تيوتروبيوم من قطعة الفم بجهاز الاستنشاق هاندي هيلر.</p><p>&nbsp;</p><p dir="RTL">المُكوِّن الآخر هو اللاكتوز أحادي الهيدرات (ربما يحتوي على كميات قليلة من بروتينات الحليب).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سبيريفا 18 ميكروجرامًا عبارة عن مسحوق استنشاق في كبسولة صلبة ذات لون أخضر فاتح مطبوع عليها كود المنتج &quot;TI&nbsp;01&quot; وشعار الشركة.</p><p>&nbsp;</p><p dir="RTL">يتوفر سبيريفا 18 ميكروجرامًا في أحجام العبوات التَّالية:</p><p dir="RTL">عبوة تحتوي على 30 كبسولة</p><p dir="RTL">عبوة تحتوي على 60 كبسولة</p><p dir="RTL">عبوة تحتوي على 90 كبسولة</p><p dir="RTL">عبوة مُركبة تحتوي على 30 كبسولة وجهاز استنشاق هاندي هيلر واحد</p><p>&nbsp;</p><p dir="RTL">كذلك، يتوفر جهاز الاستنشاق هاندي هيلر للبيع بشكل منفصل.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق</strong></p><p dir="RTL">شركة بوهرينجر إنجيلهايم إنترناشونال ذ.م.م</p><p dir="RTL">173 شارع بينجر</p><p dir="RTL">55216 إنجلهايم أيه إم راين</p><p dir="RTL">ألمانيا</p><p>&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">بوهرينجر إنجلهايم فارما ذ.م.م وشركاؤها، شراكة محدودة</p><p dir="RTL">173 شارع بينجر</p><p dir="RTL">55216 إنجلهايم أيه إم راين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             يناير 2023 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIRIVA® 18 microgram 
hard capsules with powder for inhalation
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 22.5 microgram tiotropium bromide monohydrate equivalent to 18 microgram tiotropium.
The delivered dose (the dose that leaves the mouthpiece of the HandiHaler device) is 10 microgram tiotropium.

Excipient with known effect: Each capsule contains 5.5 milligram lactose monohydrate.


For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder, hard capsule.
Light green hard capsules containing the inhalation powder, with the product code “TI 01” and company logo printed on the capsule.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SPIRIVA is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>&nbsp;</p><p>The medicinal product is intended for inhalation use only.</p><p><u>&nbsp;</u></p><p>The recommended dosage of tiotropium bromide is inhalation of the contents of one capsule once daily with the HandiHaler device at the same time of day.</p><p>&nbsp;</p><p>The recommended dose should not be exceeded.</p><p>SPIRIVA capsules are only for inhalation and not for oral intake.</p><p>SPIRIVA capsules must not be swallowed.</p><p>SPIRIVA capsules are only be inhaled with the HandiHaler device.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Geriatric patients can use tiotropium bromide at the recommended dose.</p><p>&nbsp;</p><p>Renally impaired patients can use tiotropium bromide at the recommended dose. For patients with moderate to severe impairment (creatinine clearance &pound; 50 mL/min) see section 4.4 and section 5.2.</p><p>&nbsp;</p><p>Hepatically impaired patients can use tiotropium bromide at the recommended dose (see section 5.2).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><em>COPD</em></p><p>There is no relevant use in the paediatric population (below 18 years) in the indication stated under section&nbsp;4.1.</p><p><s>&nbsp;</s></p><p><em>Cystic fibrosis</em></p><p>The safety and efficacy of Spiriva 18 microgram in children and adolescents has not been established. No data are available.</p><p><s>&nbsp;</s></p><p><strong>Method of administration</strong></p><p>&nbsp;</p><p>The HandiHaler is an inhalation device especially designed to enable patients to inhale the medication contained in SPIRIVA capsules. The HandiHaler must not be used to take any other medication. It is a single patient device intended for multiple uses.</p><p>To ensure proper administration of the medicinal product the patient should be trained on how to use the HandiHaler inhaler by the physician or by other healthcare professionals.</p><p><s>&nbsp;</s></p><p><u>Instructions for use of the HandiHaler device</u></p><p>&nbsp;</p><p>Patients should follow the steps below to use the HandiHaler.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Bild_x0020_2" o:spid="_x0000_i1038" type="#_x0000_t75"
   style='width:117pt;height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Remember to carefully follow your doctor&rsquo;s instructions for using SPIRIVA. After first use, you can use your HandiHaler for up to one year to take your medication.</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape id="Bild_x0020_3"
   o:spid="_x0000_i1037" type="#_x0000_t75" style='width:117pt;height:117pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>The HandiHaler</p><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protective cap</p><p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouthpiece</p><p>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Device base</p><p>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Piercing button</p><p>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capsule chamber</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="6" cellpadding="0"><tbody><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_4" o:spid="_x0000_i1036" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.&nbsp; To open the protective cap press the piercing button completely in and let go.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_5" o:spid="_x0000_i1035" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.&nbsp; Open the protective cap completely by pulling it upwards. Then open the mouthpiece by pulling it upwards.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_6" o:spid="_x0000_i1034" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image009.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3.&nbsp; Remove a SPIRIVA capsule from the blister (only immediately before use, see blister handling) and place it in the capsule chamber (5), as illustrated. It does not matter which way the capsule is placed in the chamber.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_7" o:spid="_x0000_i1033" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.&nbsp; Close the mouthpiece firmly<strong> </strong>until you hear a click, leaving the protective cap open.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_8" o:spid="_x0000_i1032" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image013.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image014.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.&nbsp; Hold the HandiHaler device with the mouthpiece upwards and press the piercing button completely in only once, and release. This will pierce the capsule and allows the medication to be released when you breathe in.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_9" o:spid="_x0000_i1031" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image015.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image016.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>6.&nbsp; Breathe out deeply <strong>without</strong> the device.</p><p><strong>Important</strong>:&nbsp; Please avoid breathing into the mouthpiece at any time.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_10" o:spid="_x0000_i1030" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image017.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image018.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.&nbsp; Raise the HandiHaler to your mouth and close your lips tightly around the mouthpiece. Keep your head in an upright position and breathe in slowly and deeply but at a rate sufficient to hear or feel the capsule vibrate.</p><p>Breathe in until your lungs are full; then hold your breath as long as comfortable and at the same time take the HandiHaler out of your mouth. Resume normal breathing.</p><p>&nbsp;</p><p>Repeat steps 6 and 7 once, in order to empty the capsule completely.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_11" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image019.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image020.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.&nbsp; Open the mouthpiece again. Tip out the used capsule and dispose.</p><p>&nbsp;</p><p>Close the mouthpiece and protective cap for storage of your HandiHaler device.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Cleaning the HandiHaler</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Bild_x0020_12"
   o:spid="_x0000_i1028" type="#_x0000_t75" style='width:117pt;height:117pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image021.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image022.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Clean the HandiHaler once a month. Open the protective cap and mouthpiece. Then open the base by lifting the piercing button. Rinse the complete inhaler with warm water to remove any powder. Dry the HandiHaler thoroughly by tipping excess of water out on a paper towel and air-dry afterwards, leaving the protective cap, mouthpiece and base open. <strong>It takes 24 hours to air-dry, so clean it immediately after use</strong> so that it will be ready for your next dose.</p><p>&nbsp;</p><p>If needed, the outside of the mouthpiece may be cleaned with a moist but not wet tissue.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Blister handling</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_13" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image023.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image024.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>A. Separate the SPIRIVA blister strips by tearing along the perforation.</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_14" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image025.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image026.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>B. Peel back foil (only immediately before use) using the tab until one capsule is fully visible.</p><p>In case a second capsule is exposed to air inadvertently this capsule has to be discarded.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Bild_x0020_15" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:117pt;
   height:117pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image027.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="156" height="156" src="file:///C:/Users/zayedaya/AppData/Local/Temp/msohtmlclip1/01/clip_image028.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>C. Remove capsule.</p><p>&nbsp;</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>SPIRIVA capsules contain only a small amount of powder so that the capsule is only partially filled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to the excipient lactose monohydrate (may contain small amounts of milk proteins) listed in section 6.1, or to atropine or its derivatives, e. g. ipratropium or oxitropium.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tiotropium bromide, as a once daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.&nbsp;e. rescue therapy.</p><p>&nbsp;</p><p>Immediate hypersensitivity reactions may occur after administration of tiotropium bromide inhalation powder.</p><p>&nbsp;</p><p>Consistent with its anticholinergic activity, tiotropium bromide should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction (see section 4.8).</p><p>&nbsp;</p><p>Inhaled medicines may cause inhalation-induced bronchospasm.</p><p>&nbsp;</p><p>Tiotropium should be used with caution in patients with recent myocardial infarction &lt; 6 months; any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year; hospitalisation of heart failure (NYHA Class III or IV) within the past year. These patients were excluded from the clinical trials and these conditions may be affected by the anticholinergic mechanism of action.</p><p>&nbsp;</p><p>As plasma concentration increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance &pound; 50 mL/min) tiotropium bromide should be used only if the expected benefit outweighs the potential risk. There is no long-term experience in patients with severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p>Patients should be cautioned to avoid getting the inhalation powder into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium bromide and consult a specialist immediately.</p><p>&nbsp;</p><p>Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries.</p><p>&nbsp;</p><p>Tiotropium bromide should not be used more frequently than once daily (see section 4.9).</p><p>&nbsp;</p><p>SPIRIVA capsules contain 5.5 mg lactose monohydrate. This amount does not normally cause problems in lactose intolerant patients. Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not use this medicine. The excipient lactose monohydrate may contain small amounts of milk proteins which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although no formal drug interaction studies have been performed, tiotropium bromide inhalation powder has been used concomitantly with other drugs without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, commonly used in the treatment of COPD.</p><p>&nbsp;</p><p>Use of LABA or ICS was not found to alter the exposure to tiotropium.</p><p>&nbsp;</p><p>The co-administration of tiotropium bromide with other anticholinergic-containing drugs has not been studied and is therefore not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There is a very limited amount of data from the use of tiotropium in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses (see section 5.3). As a precautionary measure, it is preferable to avoid the use of SPIRIVA during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether tiotropium bromide is excreted in human breast milk. Despite studies in rodents which have demonstrated that excretion of tiotropium bromide in breast milk occurs only in small amounts, use of Spiriva is not recommended during breast-feeding. Tiotropium bromide is a long-acting compound. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with SPIRIVA should be made taking into account the benefit of breast-feeding to the child and the benefit of SPIRIVA therapy to the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Clinical data on fertility are not available for tiotropium. A non-clinical study performed with tiotropium showed no indication of any adverse effect on fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Many of the listed undesirable effects can be assigned to the anticholinergic properties of SPIRIVA.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse drug reactions (i.&nbsp;e. events attributed to tiotropium) observed in the tiotropium group (9647 patients) from 28 pooled placebo-controlled clinical trials with treatment periods ranging from four weeks to four years.</p><p>&nbsp;</p><p>Frequency is defined using the following convention:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class /</strong><strong> MedDRA Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Taste disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Glaucoma</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Intraocular pressure increased</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Cardiac disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Atrial fibrillation</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Supraventricular tachycardia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Dysphonia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Laryngitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Sinusitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrooesophageal reflux disease</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Oropharyngeal candidiasis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Intestinal obstruction, including ileus paralytic</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Gingivitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Glossitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Dysphagia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Dental caries</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders, immune system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity (including immediate reactions)</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Skin infection, skin ulcer</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Joint swelling</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Dysuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urinary retention</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Rare</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>In controlled clinical studies, the commonly observed undesirable effects were anticholinergic undesirable effects such as dry mouth which occurred in approximately 4% of patients.</p><p>In 28 clinical trials, dry mouth led to discontinuation in 18 of 9647<strong> </strong>tiotropium treated patients (0.2 %).</p><p>&nbsp;</p><p>Serious undesirable effects consistent with anticholinergic effects include glaucoma, constipation and intestinal obstruction including ileus paralytic as well as urinary retention.</p><p><u>&nbsp;</u></p><p><u>Other special population</u></p><p>An increase in anticholinergic effects may occur with increasing age.</p><p>&nbsp;</p><p>This medicinal product contains lactose monohydrate. Lactose monohydrate may contain small amounts of milk proteins which may cause allergic reactions.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the</p><p>Federal Institute for Medicinal Products and Medical Devices (BfArM),</p><p>Dept. Pharmacovigilance, Kurt-Georg-Kiesinger-Allee&nbsp;3, D‑53175&nbsp;Bonn,</p><p>website: www.bfarm.de</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High doses of tiotropium bromide may lead to anticholinergic signs and symptoms.</p><p>&nbsp;</p><p>However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 340&nbsp;microgram tiotropium bromide in healthy volunteers. Additionally, no relevant adverse effects, beyond dry mouth, were observed following 7-day dosing of up to 170 microgram tiotropium bromide in healthy volunteers. In a multiple dose study in COPD patients with a maximum daily dose of 43 microgram tiotropium bromide over four weeks no significant undesirable effects have been observed.</p><p>&nbsp;</p><p>Acute intoxication by inadvertent oral ingestion of tiotropium bromide capsules is unlikely due to low oral bioavailability.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other drugs for obstructive airway diseases, inhalants, anticholinergics</p><p>ATC code: R03B B04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Tiotropium bromide is a long-acting, specific, muscarinic receptor antagonist, in clinical medicine often called an anticholinergic. By binding to the muscarinic receptors in the bronchial smooth musculature, tiotropium bromide inhibits the cholinergic (bronchoconstrictive) effects of acetylcholine, released from parasympathetic nerve endings. It has similar affinity to the subtypes of muscarinic receptors, M<sub>1</sub> to M<sub>5</sub>. In the airways, tiotropium bromide competitively and reversibly antagonises the M<sub>3</sub> receptors, resulting in relaxation. The effect was dose dependent and lasted longer than 24&nbsp;hours. The long duration is probably due to the very slow dissociation from the M<sub>3</sub> receptor, exhibiting a significantly longer dissociation half-life than ipratropium. As an N-quaternary anticholinergic, tiotropium bromide is topically (broncho-)selective when administered by inhalation, demonstrating an acceptable therapeutic range before systemic anticholinergic effects may occur.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The bronchodilation is primarily a local effect (on the airways), not a systemic one.</p><p>Dissociation from M<sub>2</sub> receptors is faster than from M<sub>3</sub>, which in functional in vitro studies, elicited (kinetically controlled) receptor subtype selectivity of M<sub>3</sub> over M<sub>2</sub>. The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD.</p><p>&nbsp;</p><p><em>Cardiac electrophysiology</em></p><p>Electrophysiology: In a dedicated QT study involving 53 healthy volunteers, SPIRIVA 18 mcg and 54 mcg (i.&nbsp;e. three times the therapeutic dose) over 12 days did not significantly prolong QT intervals of the ECG.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The clinical development programme included four one-year and two six-month randomised, double-blind studies in 2663 patients (1308 receiving tiotropium bromide). The one-year programme consisted of two placebo-controlled trials and two trials with an active control (ipratropium). The two six-month trials were both, salmeterol and placebo controlled. These studies included lung function and health outcome measures of dyspnoea, exacerbations and health-related quality of life.</p><p>&nbsp;</p><p><em>Lung function</em></p><p>Tiotropium bromide, administered once daily, provided significant improvement in lung function (forced expiratory volume in one second, FEV<sub>1 </sub>and forced vital capacity, FVC) within 30 minutes following the first dose which was maintained for 24 hours. Pharmacodynamic steady state was reached within one week with the majority of bronchodilation observed by the third day. Tiotropium bromide significantly improved morning and evening PEFR (peak expiratory flow rate) as measured by patient&rsquo;s daily recordings. The bronchodilator effects of tiotropium bromide were maintained throughout the one-year period of administration with no evidence of tolerance.</p><p>&nbsp;</p><p>A randomised, placebo-controlled clinical study in 105 COPD patients demonstrated that bronchodilation was maintained throughout the 24-hour dosing interval in comparison to placebo regardless of whether the drug was administered in the morning or in the evening.</p><p>&nbsp;</p><p>Clinical trials (up to 12&nbsp;months)</p><p>&nbsp;</p><p><em>Dyspnoea, Exercise tolerance</em></p><p>Tiotropium bromide significantly improved dyspnoea (as evaluated using the Transition Dyspnoea Index). This improvement was maintained throughout the treatment period.</p><p>&nbsp;</p><p><em>The impact of improvements in dyspnoea on exercise tolerance&nbsp;was investigated in two randomised, double-blind, placebo-controlled trials &nbsp;in &nbsp;433 patients with moderate to severe COPD. In these trials, six weeks of treatment with SPIRIVA significantly improved symptom-limited exercise endurance time during&nbsp;cycle ergometry at 75% of maximal work capacity by 19.7% (Trial A) and 28.3% (Trial B) compared with placebo.</em></p><p><em>&nbsp;</em></p><p><em>Health-related Quality of Life</em></p><p>In a 9-month, randomized, double-blind, placebo-controlled clinical trial of 492 patients, SPIRIVA improved health-related quality of life as determined by the St. George&rsquo;s Respiratory Questionnaire (SGRQ) total score. The proportion of patients treated with SPIRIVA which achieved a meaningful improvement in the SGRQ total score (i.&nbsp;e. &gt; 4 units) was 10.9% higher compared with placebo (59.1% in the SPIRIVA groups vs. 48.2% in the placebo group (p=0.029). The mean difference between the groups was 4.19 units (p=0.001; confidence interval: 1.69 &ndash; 6.68). The improvements of the subdomains of the SGRQ-score were&nbsp; 8.19 units for &ldquo;symptoms&rdquo;, 3.91 units for &ldquo;activity&rdquo; and 3.61 units for &ldquo;impact on daily life&rdquo;. The improvements of all of these separate subdomains were statistically significant.</p><p>&nbsp;</p><p><em>COPD Exacerbations</em></p><p>In a randomized, double-blind, placebo-controlled trial of 1829 patients with moderate to very severe COPD, tiotropium bromide statistically significantly reduced the proportion of patients who experienced exacerbations of COPD (32.2% to 27.8%) and statistically significantly reduced the number of exacerbations by 19% (1.05 to 0.85 events per patient year of exposure). In addition, 7.0% of patients in the tiotropium bromide group and 9.5% of patients in the placebo group were hospitalized due to a COPD exacerbation (p=0.056). The number of hospitalizations due to COPD was reduced by 30% (0.25‑0.18&nbsp;events per patient year of exposure).</p><p>&nbsp;</p><p>A one-year randomised, double-blind, double-dummy, parallel-group trial compared the effect of treatment with 18 microgram of SPIRIVA once daily with that of 50 microgram of salmeterol HFA pMDI twice daily on the incidence of moderate and severe exacerbations in 7376 patients with COPD and a history of exacerbations in the preceding year.</p><p>&nbsp;</p><p>Table 1: Summary of exacerbation endpoints</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>SPIRIVA<br />18 microgram (HandiHaler)</p><p>N = 3,707</p></td><td style="vertical-align:top"><p>Salmeterol<br />50 microgram (HFA pMDI)</p><p>N = 3,669</p></td><td style="vertical-align:top"><p>Ratio<br />(95% CI)</p></td><td style="vertical-align:top"><p>p-value</p></td></tr><tr><td style="vertical-align:top"><p>Time [days] to first exacerbation<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>187</p></td><td style="vertical-align:top"><p>145</p></td><td style="vertical-align:top"><p>0.83</p><p>(0.77 - 0.90)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Time to first severe (hospitalised) exacerbation<sup>&sect;</sup></p></td><td><p>-</p></td><td><p>-</p></td><td style="vertical-align:top"><p>0.72</p><p>(0.61 - 0.85)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Patients with &ge;1 exacerbation, n (%)*</p></td><td style="vertical-align:top"><p>1,277 (34.4)</p></td><td style="vertical-align:top"><p>1,414 (38.5)</p></td><td style="vertical-align:top"><p>0.90<br />(0.85 - 0.95)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Patients with &ge;1 severe (hospitalised) exacerbation, &nbsp;&nbsp;&nbsp;n (%)*</p></td><td style="vertical-align:top"><p>262 (7.1)</p></td><td style="vertical-align:top"><p>336 (9.2)</p></td><td style="vertical-align:top"><p>0.77</p><p>(0.66 - 0.89)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p>&nbsp;</p><p>&dagger;<sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Time [days] refers to 1st quartile of patients. Time to event analysis was done using Cox&#39;s proportional hazards regression model with (pooled) centre and treatment as covariate; ratio refers to hazard ratio.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Time to event analysis was done using Cox&#39;s proportional hazards regression model with (pooled) centre and treatment as covariate; ratio refers to hazard ratio. Time [days] for the 1st quartile of patients cannot be calculated, because proportion of patients with severe exacerbation is too low.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients with event were analysed using Cochran-Mantel-Haenszel test stratified by pooled centre; ratio refers to risk ratio.</p><p>&nbsp;</p><p>Compared with salmeterol, SPIRIVA increased the time to the first exacerbation (187 days vs. 145 days), with a 17% reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P&lt;0.001). SPIRIVA also increased the time to the first severe (hospitalised) exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P&lt;0.001).</p><p><u>&nbsp;</u></p><p>Long-term clinical trials (more than 1 year, up to 4 years)</p><p><u>&nbsp;</u></p><p>In a 4-year, randomised, double-blind, placebo-controlled clinical trial of 5993 randomised patients (3006 receiving placebo and 2987 receiving Spiriva), the improvement in FEV<sub>1</sub> resulting from Spiriva, compared with placebo, remained constant throughout 4 years. A higher proportion of patients completed &ge; 45 months of treatment in the Spiriva group compared with the placebo group (63.8% vs. 55.4%, p&lt;0.001). The annualized rate of decline of FEV<sub>1 </sub>compared to placebo was similar between Spiriva and placebo. During treatment, there was a 16% reduction in the risk of death. The incidence rate of death was 4.79 per 100&nbsp;patient years in the placebo group vs. 4.10 per 100 patient years in the tiotropium group (hazard ratio (tiotropium/placebo) = 0.84, 95% CI = 0.73, 0.97). Treatment with tiotropium reduced the risk of respiratory failure (as recorded through adverse event reporting) by 19% (2.09 vs. 1.68 cases per 100 patient years, relative risk (tiotropium/placebo) = 0.81, 95% CI = 0.65, 0.999).</p><p><u>&nbsp;</u></p><p><em>Tiotropium active-controlled study</em></p><p>A long-term, large scale &nbsp;randomised, double-blind, active-controlled study with an observation period up to 3 years has been performed to compare the efficacy and safety of Spiriva HandiHaler and Spiriva Respimat (5694 patients receiving Spiriva HandiHaler; 5711 patients receiving Spiriva Respimat). The primary endpoints were time to first COPD exacerbation, time to all-cause mortality and in a sub-study (906&nbsp;patients) trough FEV<sub>1 </sub>(pre-dose).</p><p>The time to first COPD exacerbation was numerically similar during the study with Spiriva HandiHaler and Spiriva Respimat (hazard ratio (Spiriva HandiHaler/Spiriva Respimat) 1.02 with a 95% CI of 0.97‑1.08). The median number of days to the first COPD exacerbation was 719 days for Spiriva HandiHaler and 756&nbsp;days for Spiriva Respimat.</p><p>The bronchodilator effect of Spiriva HandiHaler was sustained over 120 weeks, and was similar to Spiriva Respimat. The mean difference in trough FEV1 for Spiriva HandiHaler versus Spiriva Respimat was 0.010&nbsp;L (95% CI -0.018 to 0.038 L).</p><p>In the post-marketing TioSpir study comparing Spiriva Respimat and Spiriva HandiHaler, all-cause mortality including vital status follow up was similar during the study with Spiriva HandiHaler and Spiriva Respimat (hazard ratio (Spiriva HandiHaler/Spiriva Respimat) 1.04 with a 95% CI of 0.91‑1.19).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit results of studies with Spiriva in all subsets of the paediatric population in COPD and cystic fibrosis (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a) General Introduction</u></p><p>&nbsp;</p><p>Tiotropium bromide is a non-chiral quaternary ammonium compound and is sparingly soluble in water. Tiotropium bromide is administered by dry powder inhalation. Generally with the inhaled route of administration, the majority of the delivered dose is deposited in the gastro-intestinal tract, and to a lesser extent in the intended organ of the lung. Many of the pharmacokinetic data described below were obtained with higher doses than recommended for therapy.</p><p>&nbsp;</p><p><u>b) General Characteristics of the Active Substance after Administration of the Medicinal Product</u></p><p>&nbsp;</p><p><em>Absorption:</em> Following dry powder inhalation by young healthy volunteers, the absolute bioavailability of 19.5% suggests that the fraction reaching the lung is highly bioavailable. Oral solutions of tiotropium have an absolute bioavailability of 2-3%.</p><p>Maximum tiotropium plasma concentrations were observed 5-7 minutes after inhalation. At steady state, peak tiotropium plasma levels in COPD patients were 12.9 pg/mL and decreased rapidly in a multi-compartmental manner. Steady state trough plasma concentrations were 1.71 pg/mL.</p><p>Systemic exposure following the inhalation of tiotropium via the HandiHaler device was similar to tiotropium inhaled via the Respimat inhaler.</p><p>&nbsp;</p><p><em>Distribution:</em> Tiotropium has a plasma protein binding of 72% and shows a volume of distribution of 32&nbsp;L/kg. Local concentrations in the lung are not known, but the mode of administration suggests substantially higher concentrations in the lung. Studies in rats have shown that tiotropium bromide does not penetrate the blood-brain barrier to any relevant extent.</p><p>&nbsp;</p><p><em>Biotransformation:</em> The extent of biotransformation is small. This is evident from a urinary excretion of 74% of unchanged substance after an intravenous dose to young healthy volunteers. The ester tiotropium bromide is nonenzymatically cleaved to the alcohol (N-methylscopine) and acid compound (dithienylglycolic acid) that are inactive on muscarinic receptors. In-vitro experiments with human liver microsomes and human hepatocytes suggest that some further drug (&lt; 20% of dose after intravenous administration) is metabolised by cytochrome P450 (CYP) dependent oxidation and subsequent glutathion conjugation to a variety of Phase II-metabolites.</p><p>In vitro studies in liver microsomes reveal that the enzymatic pathway can be inhibited by the CYP 2D6 (and&nbsp;3A4) inhibitors, quinidine, ketoconazole and gestodene. Thus CYP 2D6 and 3A4 are involved in metabolic pathway that is responsible for the elimination of a smaller part of the dose. Tiotropium bromide even in supra-therapeutic concentrations does not inhibit CYP 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1 or&nbsp;3A in human liver microsomes.</p><p>&nbsp;</p><p><em>Elimination:</em> The effective half-life of tiotropium ranges between 27 and 45 hours in COPD patients. Total clearance was 880 mL/min after an intravenous dose in young healthy volunteers. Intravenously administered tiotropium is mainly excreted unchanged in urine (74%). After dry powder inhalation by COPD patients to steady-state, urinary excretion is 7% (1.3 &micro;g) of the unchanged drug over 24 hours, the remainder being mainly non-absorbed drug in gut that is eliminated via the faeces. The renal clearance of tiotropium exceeds the creatinine clearance, indicating secretion into the urine. After chronic once daily inhalation by COPD patients, pharmacokinetic steady state was reached by day 7 with no accumulation thereafter.</p><p>&nbsp;</p><p><em>Linearity / Nonlinearity:</em> Tiotropium demonstrates linear pharmacokinetics in the therapeutic range independent of the formulation.</p><p>&nbsp;</p><p><u>c) Characteristics in Patients</u></p><p>&nbsp;</p><p><em>Geriatric Patients:</em> As expected for all predominantly renally excreted drugs, advancing age was associated with a decrease of tiotropium renal clearance (365 mL/min in COPD patients &lt; 65 years to 271 mL/min in COPD patients &ge; 65 years).&nbsp; This did not result in a corresponding increase in AUC<sub>0-6,ss&nbsp; </sub>or C<sub>max,ss</sub> values.</p><p>&nbsp;</p><p><em>Renally Impaired Patients:</em> Following once daily inhaled administrations of tiotropium to steady-state in COPD patients, mild renal impairment (CL<sub>CR</sub><sub> </sub>50-80 mL/min) resulted in slightly higher AUC<sub>0-</sub><sub>6,ss </sub>(between 1.8&nbsp;and 30% higher) and similar C<sub>max,ss </sub>&nbsp;values compared to patients with normal renal function (CL<sub>CR</sub>&nbsp;&gt;80&nbsp;mL/min). In COPD patients with moderate to severe renal impairment (CL<sub>CR</sub>&nbsp;&lt;50&nbsp;mL/min), the intravenous administration of tiotropium resulted in doubling of the total exposure&nbsp; (82% higher AUC<sub>0‑4h</sub> and 52% higher C<sub>max</sub>) compared to COPD patients with normal renal function, which was confirmed by plasma concentrations after dry powder inhalation.</p><p>&nbsp;</p><p><em>Hepatically Impaired Patients:</em> Liver insufficiency is not expected to have any relevant influence on tiotropium pharmacokinetics. Tiotropium is predominantly cleared by renal elimination (74% in young healthy volunteers) and simple non-enzymatic ester cleavage to pharmacologically inactive products.</p><p>&nbsp;</p><p><em>Japanese COPD Patients: </em>In cross trial comparison, mean peak tiotropium plasma concentrations 10&nbsp;minutes post-dosing at steady-state were 20% to 70% higher in Japanese compared to Caucasian COPD patients following inhalation of tiotropium but there was no signal for higher mortality or cardiac risk in Japanese patients compared to Caucasian patients. Insufficient pharmacokinetic data is available for other ethnic groups.</p><p>&nbsp;</p><p><em>Paediatric Patients:</em> See section 4.2</p><p>&nbsp;</p><p><u>d) Pharmacokinetic / Pharmacodynamic Relationship(s)</u></p><p>&nbsp;</p><p>There is no direct relationship between pharmacokinetics and pharmacodynamics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Many effects observed in conventional studies of safety pharmacology, repeated dose toxicity, and reproductive toxicity could be explained by the anticholinergic properties of tiotropium bromide. Typically, in animals reduced food consumption, inhibited body weight gain, dry mouth and nose, reduced lacrimation and salivation, mydriasis and increased heart rate were observed. Other relevant effects noted in repeated dose toxicity studies were: mild irritancy of the respiratory tract in rats and mice evinced by rhinitis and epithelial changes of the nasal cavity and larynx, and prostatitis along with proteinaceous deposits and lithiasis in the bladder in rats.</p><p>&nbsp;</p><p>Harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development could only be demonstrated at maternally toxic dose levels. Tiotropium bromide was not teratogenic in rats or rabbits.</p><p>In a general reproduction and fertility study in rats, there was no indication of any adverse effect on fertility or mating performance of either treated parents or their offspring at any dosage.</p><p>The respiratory (irritation) and urogenital (prostatitis) changes and reproductive toxicity were observed at local or systemic exposures more than five-fold the therapeutic exposure. Studies on genotoxicity and carcinogenic potential revealed no special hazard for humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate (which may contain small amounts of milk proteins)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
After first opening of the blister: use capsules within the next 9 days.
Discard the HandiHaler device 12 months after first use.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C</p><p>Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/PVC/aluminium peel-off blisters, each containing 10 capsules.</p><p>The HandiHaler is a single dose inhalation device made from acrylonitrile butadiene styrene (ABS) plastic materials and stainless steel. The capsule chamber is made from methyl-methacrylate acrylonitrile butadiene styrene (MABS) or polycarbonate (PC) plastic material.</p><p>&nbsp;</p><p>Package sizes:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardboard box containing 30 capsules (3 blisters)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardboard box containing 60 capsules (6 blisters)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardboard box containing 90 capsules (9 blisters)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardboard box containing 30 capsules (3 blisters) and 1&nbsp;HandiHaler device</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hospital pack: Bundle pack containing 5 cardboard boxes of 60 capsules</p><p>&nbsp;</p><p>The HandiHaler device is also available separately packed in a cardboard box</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boehringer Ingelheim International GmbH
Binger Str. 173
55216 Ingelheim am Rhein
Germany

	Local Representative in Germany
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Str. 173
55216 Ingelheim am Rhein
Tel.: 0 800 / 77 90 900
Fax: 0 61 32 / 72 99 99
E Mail: info@boehringer-ingelheim.de
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>